In the News

CISION PR Newswire - November 15, 2023

Federal Jury Finds Guardant Health Willfully Infringes University of Washington Duplex Sequencing Patents Exclusively Licensed to TwinStrand Biosciences, Inc., Awards $83.4M in Damages; PTAB Rejects Invalidity Arguments on UW Patents

CISION PR Newswire - November 15, 2023

Federal Jury Finds Guardant Health Willfully Infringes University of Washington Duplex Sequencing Patents Exclusively Licensed to TwinStrand Biosciences, Inc., Awards $83.4M in Damages; PTAB Rejects Invalidity Arguments on UW Patents

CISION PR Newswire - August 29, 2023

TwinStrand Biosciences Announces Executive Leadership Changes to Accelerate Adoption of Duplex Sequencing for Minimal Residual Disease (MRD) Testing for Hematological Malignancies and Cell Therapy Monitoring

Business Wire - October 13, 2022

TwinStrand Biosciences Announces Leadership Transition

Globe Newswire - June 06, 2022

Singular Genomics and TwinStrand Biosciences Collaborate to Develop Ultra-high Accuracy NGS Solutions for the G4 Platform

Business Wire - June 06, 2022

TwinStrand Biosciences to Showcase Recent Applications of its Duplex Sequencing Technology at the 2022 AGBT Annual Meeting

Life Science Washington - April 20, 2022

Life Science Innovation Northwest 2022

Our CEO, Jesse Salk MD, PhD will be speaking at the Life Sciences Innovation Northwest (LSINW) 2022 Convention during the Research Tools & Medical Device session.

Wednesday, April 20th, 2022 – 2:46pm PST

Inside Precision News - April 12, 2022

How Duplex Sequencing Can Improve MRD Detection: An Interview with Jesse Salk, MD, PhD, CEO of TwinStrand Biosciences

TwinStrand Biosciences - February 24, 2022

National Firefighter Cancer Symposium 2022

This year we were proud to sponsor the scientific workshop Applying Molecular Biology & Genetic Toxicology Methods to Improve Risk Assessment and Guide Risk Management Decisions for Cancer in Firefighters at the 2022 National Cancer Fire Symposium, hosted by the Firefighter Cancer Initiative (FCI).

FNIH - February 11, 2022

TwinStrand partners with the FNIH in Project for Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)

TwinStrand Biosciences, Inc. was selected to join the FNIH Biomarkers Consortium Project aiming to establish new methods for detecting measurable residual disease (MRD) in Acute Myeloid Leukemia (AML). See the FNIH announcement here.

TwinStrand Biosciences - August 3, 2021